[Analysis of costs and profits of ambulatory care of Marfan patients after initiation of a novel German legal directive (116 b SGB V)].

  • Marie-Luise Manow
  • Nesrin Paulsen
  • Meike Rybczynski
  • Thomas Mir
  • Alexander Bernhardt
  • Hendrik Treede
  • Gunda Ohm
  • Bettina Fuisting
  • Uwe Rehder
  • Florian Meier
  • Marina Vogler
  • Thomas Meinertz
  • Karin Overlack
  • Yskert Von Kodolitsch

Related Research units

Abstract

The Marfan syndrome is a typical rare disease with multiorgan involvement and the need for specialized interdisciplinary medical care. A novel German legal directive according to section sign 116 b of the Social Statutes Book V (116 b SGB V) improves options for reimbursement and thus encourages specialized hospitals to provide ambulatory care for rare diseases such as Marfan syndrome. The authors provide the first economic analysis of section sign 116 b in a German Marfan center.

Bibliographical data

Original languageGerman
Article number8
ISSN0723-5003
Publication statusPublished - 2010
pubmed 20824410